Primary Sclerosing Cholangitis Market to Exhibit Growth at a CAGR of X% by 2032, estimates DelveInsight

Primary Sclerosing Cholangitis Market to Exhibit Growth at a CAGR of X% by 2032, estimates DelveInsight

DelveInsight’s ‘Primary Sclerosing Cholangitis Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an in-depth understanding of the Primary Sclerosing Cholangitis, historical and forecasted epidemiology as well as the market trends in the United States, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan.

 

Key Takeaways from the Primary Sclerosing Cholangitis Market Report

  • The increase in Primary Sclerosing Cholangitis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
  • As per DelveInsight analysis, the Primary Sclerosing Cholangitis Market is anticipated to witness growth at a considerable CAGR.
  • The leading Primary Sclerosing Cholangitis Companies working in the market include Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others.
  • Promising Primary Sclerosing Cholangitis Therapies in the various stages of development include Ritivixibat, Cenicriviroc 150 mg, HK-660S, Elafibranor 80 mg, Volixibat, PLN-74809, and others.
  • April 2024:- Pliant Therapeutics Inc.- A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC). A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis.
  • April 2024:-Mirum Pharmaceuticals Inc.- A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis. The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.

 

Discover which therapies are expected to grab the Primary Sclerosing Cholangitis Market Share @ Primary Sclerosing Cholangitis Market Outlook

 

Primary Sclerosing Cholangitis Overview

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by inflammation and scarring (fibrosis) of the bile ducts inside and outside the liver. Bile ducts are the tubes that carry bile (a digestive fluid produced by the liver) from the liver to the gallbladder and small intestine. In PSC, inflammation and scarring narrow and block the bile ducts, leading to problems with bile flow and causing damage to the liver over time.

 

Primary Sclerosing Cholangitis Epidemiology Insights

The epidemiology section of Primary Sclerosing Cholangitis offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

 

Download the report to understand which factors are driving Primary Sclerosing Cholangitis Epidemiology trends @ Primary Sclerosing Cholangitis Epidemiological Insights

 

Primary Sclerosing Cholangitis Drugs Market

The Primary Sclerosing Cholangitis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Primary Sclerosing Cholangitis signaling in Primary Sclerosing Cholangitis are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Primary Sclerosing Cholangitis Treatment Market Landscape

The Primary Sclerosing Cholangitis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Primary Sclerosing Cholangitis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To learn more about Primary Sclerosing Cholangitis treatment guidelines, visit @ Primary Sclerosing Cholangitis Treatment Market Landscape

 

Primary Sclerosing Cholangitis Market Outlook

The report’s outlook on the Primary Sclerosing Cholangitis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Primary Sclerosing Cholangitis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Primary Sclerosing Cholangitis drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Primary Sclerosing Cholangitis market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Primary Sclerosing Cholangitis Drugs Uptake

The drug chapter of the Primary Sclerosing Cholangitis report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Primary Sclerosing Cholangitis.

 

Major Primary Sclerosing Cholangitis Companies

Several Primary Sclerosing Cholangitis Companies working in the market include Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others.

 

Learn more about the FDA-approved drugs for Primary Sclerosing Cholangitis @ Drugs for Primary Sclerosing Cholangitis Treatment

 

Scope of the Primary Sclerosing Cholangitis Market Research Report

  • Coverage- 7MM
  • Primary Sclerosing Cholangitis Companies- Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others.
  • Primary Sclerosing Cholangitis Pipeline Therapies- Ritivixibat, Cenicriviroc 150 mg, HK-660S, Elafibranor 80 mg, Volixibat, PLN-74809, and others.
  • Primary Sclerosing Cholangitis Market Dynamics: Primary Sclerosing Cholangitis Market Drivers and Barriers
  • Primary Sclerosing Cholangitis Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Primary Sclerosing Cholangitis Drugs in development @ Primary Sclerosing Cholangitis Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Report Introduction

3. Primary Sclerosing Cholangitis (PSC) Market Overview at a Glance

4. Executive Summary of Primary Sclerosing Cholangitis (PSC)

5. Disease Background and Overview

6. Epidemiology and Patient Population

7. Patient Journey

8. Emerging Therapies

10. Primary Sclerosing Cholangitis (PSC): Seven Major Markets + Nordic Countries Market Analysis

11. SWOT Analysis

12. Unmet Needs

13. KOL Views

14. Market Access and Reimbursement

15. Acronyms and Abbreviations

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/